First international consensus guidelines on use of polymyxins are out
An international panel of the leading researchers on infectious disease and antimicrobials has formed new guidelines on the use of polymyxins. Polymyxins are a class of antibiotics employed as a last resort to treat deadly, drug-resistant bacteria or superbugs.
The guidelines, published in Pharmacotherapy, set new standards for the clinical use of polymyxins, including on maximum dosage, treatment strategies and best practice for use in combination with other antibiotics.
The recommendations have been endorsed worldwide by six international societies and organizations across the globe: American College of Clinical Pharmacy, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, International Society for Anti-infective Pharmacology, Society of Critical Care Medicine and Society of Infectious Diseases Pharmacists.
Polymyxin, an antibiotic first introduced in the 1950s fell out of favor due to their toxicity to the kidneys. However, the drug was recently resurrected by researchers and clinicians to aid in the fight against increasingly antibiotic-resistant bacteria, more commonly known as superbugs
Polymyxin, an antibiotic first introduced in the 1950s fell out of favor due to their toxicity to the kidneys. However, the drug was recently resurrected by researchers and clinicians to aid in the fight against increasingly antibiotic-resistant bacteria, more commonly known as superbugs.
There is wide variation in clinical standards that guide the use of Polymyxin leading to considerable confusion among clinicians on how to best use this last line antibiotic and correct dose of the drug.
The recent publication provides clinicians with 34 recommendations for using polymyxin B and colistin – also known as polymyxin E. Highlights from the paper include:
The maximum tolerable dosage of polymyxin B and colistin is set at two milligrams per liter.
Polymyxin B is preferred for routine systemic use against invasive infections, while colistin is preferred for the treatment of lower urinary tract infections and for delivery to the heart, brain and spinal canal.
Patients receiving polymyxins should avoid agents that are toxic to the kidneys, such as nonsteroidal anti-inflammatory drugs (common pain relievers that include aspirin and ibuprofen) and angiotensin-converting-enzyme inhibitors (drugs used primarily to treat hypertension and congestive heart failure).
To reduce confusion over labeling conventions used in different parts of the world, hospitals and prescription orders should specify doses of colistin in either international units (IU) or milligrams of colistin base activity (CBA).
In the treatment of the superbugs carbapenem-resistant P. aeruginosa (CRPA) and carbapenem-resistant Enterobacteriaceae (CRE), polymyxins should be used in combination with one or more antibiotics, ideally a drug the bacteria is susceptible to.
In the treatment of the superbug carbapenem-resistant A. baumannii (CRAB), polymyxins should only be used in combination with an antibiotic that the bacteria is susceptible to. If no such drug is available, the polymyxin should be delivered alone.
“There is considerable confusion on how to optimally use the polymyxin antibiotics,” said Brian Tsuji, PharmD, professor of pharmacy practice in the University at Buffalo School of Pharmacy and Pharmaceutical Sciences.
“These guidelines represent consensus recommendations from expert clinicians and scientists around the globe to guide polymyxin therapy in Gram-negative infections where no treatments appear to exist.”